European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 23 · Tue 17 Nov 

Trials

2025-522312-16-00

EU Clinical Trials Information System

Trial ID
T-ctis-2025-522312-16-00
Registry
EU Clinical Trials Information System
CTIS number
2025-522312-16-00
Asset
brenipatide (LY3537031)
Sponsor, as registered
Eli Lilly & Co.
Phase
Therapeutic confirmatory (Phase III)
Indication
Alcohol Use Disorder
Status
Authorised
Start date
27/02/2026
Primary completion
CTIS does not publish one.
Member states concerned
Belgium, Germany
Sites
10

Member states whose regulator has a decision on this trial.

euclinicaltrials.euctis registryverified 2026-11-07

Notes on the record

Supersedes the row verified 2026-09-15 (kept), per DATA LAYER rule 4. Read from the CTIS public API retrieve endpoint 2026-11-07 (https://euclinicaltrials.eu/ctis-public-api/retrieve/2025-522312-16-00; response sha256 74903d004804). primary_completion_date is EMPTY because CTIS does not publish one. Per-state authorisation is NOT recorded and status codes are recorded verbatim, not decoded: the registry publishes no key. Brenipatide, AUD. Germany lastDecisionDate 2026-11-02T10:36:55 (was 2026-09-10 in the collector's read); Belgium 2026-10-09; both mscPublicStatusCode 4; member states BE and DE unchanged. The API does not expose what the decision was.

Company

Through brenipatide (LY3537031): Lilly

Cited in

Issues quoting 2025-522312-16-00 in their own text.

Record history